Michael Marco, MD

Colorectal surgeon, Researcher, Husband, Father

[Michael Marco, MD @DMichaelmarco]

@Doc_JinKim @USFHealth Hope all is ok. Stay safe Jin.

[Michael Marco, MD @DMichaelmarco]

The genomic landscape of 2,023 colorectal cancers | Nature. New insights into the genomic diversities of CRC using WGS. Interesting findings about different genomics in young onset CRC.

#ColorectalCancer #YoungOnset #Genomics #CancerResearch https://t.co/uBWh1xJsRA

[DCRjournal @DCRjournal]

#DCRJournal visual abstract | Sacral Neuromodulation in Patients With Low Anterior Resection Syndrome: The SANLARS Randomized Clinical Trial: https://t.co/BsNrVbjgxL

@JohnRTMonsonMD @jendavidsmd @ScottRSteeleMD @Swexner @me4_so @ACPGBI @drtracyhull @ASCRS_1

[DCRjournal @DCRjournal]

TNT for anal adenocarcinoma and watch and wait. Read more in this month's #DCRJournal: https://t.co/XB4mKkY8Ra

@JohnRTMonsonMD @jendavidsmd @ScottRSteeleMD @Swexner @me4_so @ACPGBI @drtracyhull @ASCRS_1

[Stefan Holubar MD MS @HolubarStefan]

SPICY: Hot off the press at #ECCO2024 / first RCT of mesenteric excision for ileocolic #Crohn #IBDSurgery -> no effect on postop endoscopic recurrence from #AmsterdamMedicalCenter

[ChainReaper @_Chain_Reaper_]

Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial | Oncology | JAMA Network Open | JAMA Network https://t.co/XIVIYUmCav

[Josh Smith, MD, PhD, FACS @JoshSmithMDPhD]

Congrats to all of the OPRA investigators and @DrGarciaAguilar - 5-year data presented today by Floris Verheij @MSKCancerCenter ; LCRT --> FOLFOX: higher rates of organ preservation, lower rates of local regrowth AND no decrement in oncologic outcomes @ASCO; #ASCO23 @ASCRS_1

[Michael Marco, MD @DMichaelmarco]

@fsanchezvega @MSKCancerCenter @chatila_w @hswalch Great work!!

[Michael Marco, MD @DMichaelmarco]

@Farrukh2132 @AHPBA @Rutgers_NJMS @NJMSDeptSurgery Congrats !!

[Josh Smith, MD, PhD, FACS @JoshSmithMDPhD]

Now to the DMT with a distinguished panel #MSKcolorectalCME @MSKCancerCenter - low Rectal pMMR cancer - what to do? Treated via OPRA trial (pre-Janus)

[Mark Soliman, MD, MBA @MarkSoliman]

We’re really, really excited to get this @ASCRS_1 Research Foundation funded study done! Just a little Hurricane to deal with first and off to the races.

See you all ar #occ2022!

[ChainReaper @_Chain_Reaper_]

Mid/Lower #RectalCancer --> #Chemo First or #Radiation First: Does It Really Matter? Join me and other esteemed colleagues at the #MSKcolorectalCME on Nov. 11-12 @MSKCancerCenter where we'll delve into these complexities. Don't miss your chance to join us: https://t.co/JdyyljwOzw

[Josh Smith, MD, PhD, FACS @JoshSmithMDPhD]

Another excellent talk by E Fokas on the rationale for and progress of ACO/ARO/AIO-18.1 - see that accrual folks!! - tells you the importance of having watch-and-wait integrated in the context of a modern Rectal cancer trial #Ficare2022 #OrganPreservation

[Michael Marco, MD @DMichaelmarco]

@studniarek_adam @WeillCornell @MSKCancerCenter @NJMSDeptSurgery @DrGuarrera @DrGarciaAguilar @GGanttMD @DoctorHoRo Congrats and welcome to our family !

[ChainReaper @_Chain_Reaper_]

Join us (in-person/virtually) for the 6th Advances in #Colorectal Oncology Symposium this Nov. 11-12 @MSKCancerCenter
This year's exciting program features world-renowned experts in the field of #colorectalcancer #rectalcancer #MSKcolorectalCME Register: https://t.co/JdyyljwOzw

[Towards New Standards 2024 @TNSSymp_2024]

Wonderful presentation of @R_Perez_MD @TNS_2022 on near cCR. Take home message: immediate surgery if cCR is not achieved - delayed surgery results in worse survival.

[Towards New Standards 2024 @TNSSymp_2024]

Last speaker of the evening: the world renowned @DrGarciaAguilar. He discusses the response prediction to neoadjuvant therapy and clinical implications.

[Michael Marco, MD @DMichaelmarco]

Very proud of our latest publication in Nature Medicine! One size doesn’t fit all in rectal cancer! Rectal Tumor biology affect the response to the neoadjuvant therapy #colorectalcancer

[ChainReaper @_Chain_Reaper_]

See our latest work in rectal cancer. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer | Nature Medicine https://t.co/6PKEUlifhX

[Andrea Cercek @AndreaCercek]

Very proud of our study published in @NEJM. 100% clinical complete response with dostarlimab alone in mismatch repair-deficient locally advanced #RectalCancer. No radiation or surgery! @ASCO #ASCO22 @MSKCancerCenter https://t.co/sZypoHBtj7

[Rodrigo O Perez @R_Perez_MD]

International rectal cancer forum is back!! Yes 2022!! Yes in person!! Mark your calendar now!! Hosted by the queen in coloproctology prof. Angelita Habr-Gama October 31st and November 1st. Don’t miss it!!